{"sentence_labels": [1, -1, -1, -1, -1], "text": "Patient baseline characteristics in the FAS were generally comparable between the treatment groups [17] . The proportion of patients undergoing single-day or multiple-day chemotherapy (regardless of emetogenicity) was broadly similar across treatment groups between cycles (supplementary table 1). The majority of patients were male (262 [53.1%] of 493), white (469; 95.1%), and median age was 7.1 years (range: 2.1 months to 16.9 years). Across the palonosetron (10 and 20 \u03bcg/kg) and ondansetron treatment groups, the numbers of patients with primary cancers at baseline were balanced, and most patients received MEC regimens ( As previously reported [17] , in the acute phase of the first on-study chemotherapy cycle, noninferiority versus ondansetron was shown for 20 \u03bcg/kg palonosetron (\u0394CR: 0.36% [97.5% CI: -11.7-12.4]; p = 0.0022). Noninferiority versus ondansetron was not demonstrated for 10 \u03bcg/kg palonosetron in the acute phase (\u0394CR: -4.41% [97.5% CI: -16.4-7.6]).", "section": "\u2022 \u2022 Patients & characteristics", "classification_label": 0, "section_number": 17, "sentences": ["Patient baseline characteristics in the FAS were generally comparable between the treatment groups [17] .", "The proportion of patients undergoing single-day or multiple-day chemotherapy (regardless of emetogenicity) was broadly similar across treatment groups between cycles (supplementary table 1).", "The majority of patients were male (262 [53.1%] of 493), white (469; 95.1%), and median age was 7.1 years (range: 2.1 months to 16.9 years).", "Across the palonosetron (10 and 20 \u03bcg/kg) and ondansetron treatment groups, the numbers of patients with primary cancers at baseline were balanced, and most patients received MEC regimens ( As previously reported [17] , in the acute phase of the first on-study chemotherapy cycle, noninferiority versus ondansetron was shown for 20 \u03bcg/kg palonosetron (\u0394CR: 0.36% [97.5% CI: -11.7-12.4]; p = 0.0022).", "Noninferiority versus ondansetron was not demonstrated for 10 \u03bcg/kg palonosetron in the acute phase (\u0394CR: -4.41% [97.5% CI: -16.4-7.6])."], "doc_id": "34315"}